HIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...
In a study of 12 participants, researchers at Beth Israel Deaconess Medical Center (BIDMC) have demonstrated that a cocktail ...
Standard treatment of babies with HIV typically starts two to three months after birth and continues for decades. This new ...
Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen ...
Future modifications of the GSS/PSS scores and of bioinformatics-based methods are needed to improve the choice of optimized therapy in pivotal studies of new HIV drugs and in the clinical care of ...
The largest-ever study of women in sub-Saharan Africa zeroes in on the combination of bacterial vaginosis-associated bacteria ...
The Joint United Nations Programme on HIV/AIDS (UNAIDS) has raised alarm over the increasing incidence of HIV among young ...
Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...
Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...
Twice-a-year-PReP will only fulfill its potential if Medicaid takes decisive action to ensure it is accessible to the ...
Progress in preventing infections was being made in the country with Europe's second-highest number of HIV cases. Then came ...
The use of Pre-exposure Prophylasix (PrEP) has expanded significantly over the past few years contributing to reduction of new HIV infections.